New scan could sharpen prostate cancer detection

NCT ID NCT07485881

Not yet recruiting Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will compare a newer imaging method called 18F-PSMA PET/CT with the standard CT scan for prostate cancer patients. The goal is to see if the new scan is better at finding cancer initially, checking how well treatment is working, and detecting cancer that has come back. About 59 patients will be enrolled, and the results could help doctors make more informed decisions about treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-PSMA (a radioactive tracer for PET imaging)
What this could lead to: If this works, it could show that 18F-PSMA PET/CT is better than standard CT at detecting and monitoring prostate cancer, leading to more accurate staging and treatment decisions.
What could go wrong: This is a small, early-stage study with only 59 participants, so results may not apply to all patients. The new scan may not prove significantly better than CT, and there are risks like claustrophobia or radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATE CANCER - RECURRENT PROSTATE CANCER METASTATIC

More trials for these conditions

Other studies related to the condition(s) this trial covers.